Sacituzumab govitecan
About
Therapy type: Targeted therapy
Therapy strategy: Topoisomerase inhibition
Mappings
NCI Thesaurus: Sacituzumab Govitecan (coding:ncit:C102783)
RxNorm: sacituzumab govitecan (coding:rxcui:2360232, coding:omop:1145485)
Therapeutic response
Precision oncology relationships for therapeutic response involving this therapy.
Organizations
Biomarkers
Cancer types
Therapies
| Organizations | Biomarkers | Cancer types | Therapies | |
|---|---|---|---|---|
| EMA (2) FDA (2) | ER negative, HER2-negative, PR negative | Invasive Breast Carcinoma | Sacituzumab govitecan | |
| EMA (1) FDA (2) | ER positive, HER2-negative | Invasive Breast Carcinoma | Sacituzumab govitecan | |
| EMA (1) FDA (2) | HER2-negative, PR positive | Invasive Breast Carcinoma | Sacituzumab govitecan | |
| EMA (1) FDA (2) | ER positive, HER2-negative, PR positive | Invasive Breast Carcinoma | Sacituzumab govitecan |